Hrt Financial LP Arrowhead Pharmaceuticals, Inc. Transaction History

Hrt Financial LP

$15.6 Billion
Q1 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$21.2 - $31.03 $145,665 - $213,207	-6,871 Reduced 45.92%	8,091 $247,000
Q3 2023 Nov 13, 2023	SELL	$26.2 - $36.08 $1.72 Million - $2.37 Million	-65,577 Reduced 81.42%	14,962 $402,000
Q2 2023 Aug 11, 2023	BUY	$25.16 - $41.38 $1.63 Million - $2.68 Million	64,693 Added 408.26%	80,539 $2.87 Million
Q1 2023 May 12, 2023	BUY	$23.68 - $38.51 $375,233 - $610,229	15,846 New	15,846 $402,000
Q2 2022 Aug 12, 2022	BUY	$27.79 - $50.61 $709,228 - $1.29 Million	25,521 New	25,521 $898,000

Q4 2021 Feb 14, 2022	SELL	$58.09 - $82.51 $1.93 Million - $2.75 Million	-33,301 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$58.38 - $84.96 $422,496 - $614,855	-7,237 Reduced 17.85%	33,301 $2.08 Million
Q2 2021 Aug 16, 2021	BUY	$62.15 - $90.32 $2.52 Million - $3.66 Million	40,538 New	40,538 $3.36 Million
Q1 2021 May 17, 2021	SELL	$61.35 - $90.47 $4.03 Million - $5.94 Million	-65,649 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$43.82 - $85.37 $2.88 Million - $5.6 Million	65,649 New	65,649 $5.04 Million
Q1 2020 May 15, 2020	SELL	$20.56 - $63.12 $6.15 Million - $18.9 Million	-299,297 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$28.14 - $73.01 $8.42 Million - $21.9 Million	299,297 New	299,297 $19 Million
Q3 2019 Nov 14, 2019	SELL	$26.26 - $34.86 $267,142 - $354,630	-10,173 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$17.43 - $28.82 $177,315 - $293,185	10,173 New	10,173 $269,000
Q1 2019 May 14, 2019	SELL	$12.05 - $20.18 $332,495 - $556,826	-27,593 Closed	0 $0
Q4 2018 Feb 15, 2019	BUY	$10.74 - $19.7 $296,348 - $543,582	27,593 New	27,593 $342,000

Others Institutions Holding ARWR

# of Institutions

296

Shares Held

88.5M

Call Options Held

905K

Put Options Held

387K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.71B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.

Account